digital therapeutics

What the loss of one of the earliest and most well-known companies in the digital health space tells us about digital health and pharma.

With the abrupt transition to telehealth, the paradigm of care has shifted from legacy thinking to digital innovation

Proceeds will be used to drive growth of its core digital therapy platforms for people managing musculoskeletal conditions and fund expansions into new conditions.

The news comes months after reports that the company had furloughed staff and couldn't secure additional funding for its-ingestible sensor business.

The long-awaited decision is the first regulatory authorization for Akili, and the first game-based therapeutic that the FDA has greenlit for any condition.

Healthcare providers use a web interface to prescribe an initial dose "and BlueStar does the rest," according to Welldoc's chief medical officer.

MobiHealthNews talks about the value of digital therapeutics, artificial intelligence and learnings from COVID-19 with Dr Cesar Morcillo Serra, director of internal medicine in Hospital Cima Sanitas Barcelona, Spain.

In response to recent COVID-19 guidance, the company is releasing its video game-like treatment to qualifying families at no cost, and without explicitly requiring a doctor's prescription.

The monitoring system will help medics triage patients with the virus.

Also: FDA COVID-19 policy allows for remote use, digital modifications to ophthalmic devices; 23andMe launches genetics study to understand varying COVID-19 responses.